Dollar Slips as Risk Appetite Grows Amid Nvidia Rally and Iran Peace Hopes 
Fed’s Anna Paulson Signals Rates Could Stay Higher Longer Amid Inflation Risks 
Dollar Eases as US-Iran Peace Deal Report Impacts Forex and Bond Markets 
ECB Signals Possible Rate Hike as Middle East Tensions Push Euro Zone Inflation Higher 
Rubio to Push NATO Defense Spending, Strengthen India Ties During Key Diplomatic Tour 
UK Hiring Slows as Iran War Fuels Economic Uncertainty in 2026 
Oil Prices Climb as Trump Warns of Possible U.S. Strike on Iran 
Gold Prices Slip as Iran Conflict and Fed Rate Hike Fears Weigh on Market Sentiment 
Asian Stocks Slide Ahead of Nvidia Earnings as Tech Shares Tumble 
Australia Regulator Flags Private Credit Risks Amid Global Market Uncertainty 
China Keeps Loan Prime Rates Steady for 12th Month as PBOC Signals Cautious Policy Approach 
Japan Posts Strong April Trade Surplus as Exports Surge Amid Robust U.S. and China Demand 
China to Buy 200 Boeing Jets, Push for Extended U.S. Trade Deal 
Oil Tankers Exit Strait of Hormuz as Trump Signals Possible Iran Deal 
Oil Prices Slip as Trump Signals Quick End to Iran Conflict 
US Stock Futures Slip as Nvidia Earnings Fail to Fully Impress Investors 
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
